F17464
Проводит Пьер Фабре Медикамент
Страница компанииДействие препарата F17464 при применении для лечения острых приступов шизофрении
Постоянная ссылка: https://clinomir.ru/trials/permit/ru/684/2014-12-01/
Источник: ГРЛС — Государственный реестр лекарственных средств Минздрава России; ClinicalTrials.gov (U.S. National Library of Medicine); clinmarket. Что откуда
Простыми словами
Словарь терминов- Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–64 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 90 чел. в стране «Россия».
- Центров в реестре: 12 в 10 городах. Список — ниже на странице.
- Плановая дата окончания (01.2016) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 14 · невключение: 22
Критерии включения
- Demographic and other characteristics
- Male or female, 18-64 years of age inclusive
- primary diagnosis of schizophrenia undergoing an acute exacerbation with prominent "active phase" symptoms, as described by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition - Text Revision (DSM IV-TR) using the MINI 6.0 (Mini-International Neuropsychiatric Interview) for schizophrenia and psychotic disorders related to DSM IV-TR
- Well-documented diagnosis of schizophrenia for a minimum of 1 year before the screening visit
- Since the diagnosis of schizophrenia, the average number of hospitalisations should be no higher than 2 per year (the minimum duration of hospitalization should be more than 4 days)
- During the year before Visit 1, maximum 3 acute psychotic episodes that required hospitalization or change of antipsychotic medication or other therapeutic intervention
- Adequate clinical response to well-conducted treatment courses during previous acute episodes. A well conducted treatment course is defined as an antipsychotic treatment with the usual doses for at least 4 weeks
- Current acute episode
- Structured Clinical Interview for the Positive And Negative Syndrome Scale (SCI-PANSS) with a PANSS total score ≥ 70 to < 120 (at Visit 1 and 2)
- Rating of at least 4 (moderate) on at least 2 of the following 4 PANSS positive symptoms: delusions, hallucinatory behaviour, conceptual disorganization, suspiciousness/persecution
- Clinical Global Impression of Severity (CGI-S) score ≥ 4 (moderate or severe)
- Antipsychotic initiated for this acute episode and/or ongoing chronic antipsychotic treatment, with a maximum of 2 antipsychotics in total needed to be changed (due to inefficacy or safety reasons)
- Hospitalization and/ or treatment for the current psychotic episode for less than 2 weeks prior to Visit 1
- No significant improvement of PANSS total score between enrolment (Visit 1) and inclusion (Visit 2) corresponding to a score improvement < 20% on positive symptoms subscale
Критерии невключения
- Related to the pathology
- Patients in their first acute episode of psychosis
- Current schizophrenic episode with predominant negative symptoms
- Patient " known to be refractory " defined as lack of significant improvement (no significant relief of symptoms, and no period of good function) despite adequate courses with at least 3 different antipsychotics medication cycles of an adequate duration (at least 4 weeks) and at adequate dosage during the previous 5 years;
- Schizoaffective disorder, schizophreniform disorder and other psychotic disorders;
- Bipolar I and II disorder
- Pervasive developmental disorder, mental retardation, delirium, dementia, memory impairment and other cognitive disorders that would compromise a reliable assessment according to the investigator's opinion
- Known or suspected borderline or antisocial personality disorder or other DSM IV axis II disorder of sufficient severity to interfere with participation in this study
- History of tardive dyskinesia or chronic extra-pyramidal symptoms (EPS), serotonin syndrome or neuroleptic malignant syndrome
- Major depressive disorder which requires a pharmacological treatment
- At imminent risk of injuring him/herself or others or causing significant damage to property, as judged by the investigator
- Suicidal risk based on the Columbia-Suicide Severity Rating Scale (C-SSRS)
- Any suicidal behavior in the past year
- Suicidal ideation of type 4 or 5 in the past month
- Related to treatments
- Structured psychotherapy (e.g. cognitive behavioural therapy) started within 6 weeks before visit 1
- Electroconvulsive therapy within 3 months before Visit 1
- Previous lack of response to electroconvulsive therapy
- Treatment ongoing with a depot neuroleptic (even if less than 1 cycle in duration before Visit 1)
- Patient having previous treatment course with clozapine within the 4 months prior to Visit 1
- Requirement of concomitant treatment with any of the prohibited medications
- History of intolerance or hypersensitivity to other drugs of the same chemical class as F17464 or to rescue medications or any history of severe drug allergy or hypersensitivity
Источник: ClinicalTrials.gov, NCT02151656 · запись обновлена в реестре 16 декабря 2016.
Дизайн и результаты
Что измеряют — первичные конечные точки (1)
- Change of the Positive and Negative Syndrome Scale (PANSS) total score — Day 43
Цель исследования
The purpose of this study is to evaluate the potential efficacy of oral F17464 in comparison to placebo over 6 weeks in patients with acute exacerbation of schizophrenia. Study design: double-blind, randomized, placebo-controlled, parallel-groups, fixed-dose design, multicentre study.
Области и заболевания
Где проходит
12 центров в 10 городахОткуда эта информация
-
ГРЛС — Государственный реестр лекарственных средств Минздрава России · № 684 от 01.12.2014 Официальный реестр · загружено 1 октября 2026Препарат, номер протокола, название, разрешение, фаза, сроки, число участников, спонсор, разработчик, центры
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT02151656 Официальный реестр (США) · загружено 9 ноября 2026Цель
-
clinmarket · № 4052 Каталог исследований · загружено 1 октября 2026Статус
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.